Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen - PubMed (original) (raw)
Case Reports
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
Nikolaos Spanakis et al. Int J Antimicrob Agents. 2014 Dec.
Abstract
Serological, molecular and phylogenetic analyses of a recently imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) in Greece are reported. Although MERS-CoV remained detectable in the respiratory tract secretions of the patient until the fourth week of illness, viraemia was last detected 2 days after initiation of triple combination therapy with pegylated interferon, ribavirin and lopinavir/ritonavir, administered from Day 13 of illness. Phylogenetic analysis of the virus showed close similarity with other human MERS-CoVs from the recent Jeddah outbreak in Saudi Arabia. Immunoglobulin G (IgG) titres peaked 3 weeks after the onset of illness, whilst IgM levels remained constantly elevated during the follow-up period (second to fifth week of illness). Serological testing confirmed by virus neutralisation assay detected an additional case that was a close contact of the patient.
Keywords: Antiviral treatment; Coronavirus; MERS; MERS-CoV; Phylogeny; Serology.
Copyright © 2014. Published by Elsevier B.V.
Figures
Fig. 1
Time course of symptoms, medication, and molecular and serological findings of the Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patient. IIF, indirect immunofluorescence.
Fig. 2
Phylogenetic tree of the Middle East respiratory syndrome coronavirus (MERS-CoV) from the Greek patient. Nucleotide sequences of 3-kb concatenated sequences of representative MERS-CoVs were analysed and a phylogenetic tree was constructed by the PhyML method. Values at the branches show the result of the approximate likelihood ratio, with values of <0.70 not depicted.
Similar articles
- Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Kim UJ, et al. Antivir Ther. 2016;21(5):455-9. doi: 10.3851/IMP3002. Epub 2015 Oct 22. Antivir Ther. 2016. PMID: 26492219 - Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA; And the MIRACLE trial group. Arabi YM, et al. Trials. 2018 Jan 30;19(1):81. doi: 10.1186/s13063-017-2427-0. Trials. 2018. PMID: 29382391 Free PMC article. - The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015.
Lee JY, Kim YJ, Chung EH, Kim DW, Jeong I, Kim Y, Yun MR, Kim SS, Kim G, Joh JS. Lee JY, et al. BMC Infect Dis. 2017 Jul 14;17(1):498. doi: 10.1186/s12879-017-2576-5. BMC Infect Dis. 2017. PMID: 28709419 Free PMC article. - MERS-CoV: Understanding the Latest Human Coronavirus Threat.
Chafekar A, Fielding BC. Chafekar A, et al. Viruses. 2018 Feb 24;10(2):93. doi: 10.3390/v10020093. Viruses. 2018. PMID: 29495250 Free PMC article. Review. - Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Al-Tawfiq JA, Memish ZA. Al-Tawfiq JA, et al. Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275. doi: 10.1080/14787210.2017.1271712. Epub 2016 Dec 24. Expert Rev Anti Infect Ther. 2017. PMID: 27937060 Free PMC article. Review.
Cited by
- Potential Therapeutic Options for COVID-19.
Zheng X, Li L. Zheng X, et al. Infect Microbes Dis. 2020 Jul 16;2(3):89-95. doi: 10.1097/IM9.0000000000000033. eCollection 2020 Sep. Infect Microbes Dis. 2020. PMID: 38630098 Free PMC article. Review. - [Use of ribavirin in viruses other than hepatitis C. A review of the evidence].
Ramírez-Olivencia G, Estébanez M, Membrillo FJ, Ybarra MDC. Ramírez-Olivencia G, et al. Enferm Infecc Microbiol Clin. 2019 Nov;37(9):602-608. doi: 10.1016/j.eimc.2018.05.008. Epub 2018 Jun 12. Enferm Infecc Microbiol Clin. 2019. PMID: 38620198 Free PMC article. Review. Spanish. - Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.
Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, Kane B, Keesari PR, Pulakurthi YS, Sheffels E, Balasubramanian P, Chibbar R, Chittajallu S, Cowie K, Karon J, Siegel L, Tarchand R, Zinn C, Gupta N, Kallmes KM, Saravu K, Touchette J. Vegivinti CTR, et al. BMC Infect Dis. 2022 Jan 31;22(1):107. doi: 10.1186/s12879-022-07068-0. BMC Infect Dis. 2022. PMID: 35100985 Free PMC article. - Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?
Kumar N, AbdulRahman A, AlAwadhi AI, AlQahtani M. Kumar N, et al. Sci Rep. 2021 Sep 28;11(1):19213. doi: 10.1038/s41598-021-98712-3. Sci Rep. 2021. PMID: 34584152 Free PMC article. - Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady A, Lee J, Loboda ZA. Hamady A, et al. Infection. 2022 Feb;50(1):11-25. doi: 10.1007/s15010-021-01664-z. Epub 2021 Jul 29. Infection. 2022. PMID: 34324165 Free PMC article. Review.
References
- European Centre for Disease Prevention and Control . ECDC; 2 July 2014. Epidemiological update: Middle East respiratory syndrome coronavirus (MERS-CoV) http://www.ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.asp... [accessed 9 September 2014]
- Al-Tawfiq J.A., Memish Z.A. What are our pharmacotherapeutic options for MERS-CoV? Expert Rev Clin Pharmacol. 2014;7:235–238. - PubMed
- Clinical Decision Making Tool for Treatment of MERS-CoV v.1.1, 29 July, 2013. Public Health England. http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.... [accessed 11 September 2014].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources